Related Experiment Video
Updated: Dec 27, 2025
07:47
The Slice Culture Method for Following Development of Tooth Germs In Explant Culture
Published on: November 13, 2013
14.6K
Fingolimod for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia
Hussein Algahtani1, Bader Shirah2, Yaser Al Malik3
1King Abdulaziz Medical City/King Saud bin Abdulaziz University for Health Sciences.
Clinical Neuropharmacology
|February 28, 2020
Summary
Fingolimod effectively reduced relapses and improved MRI scans in Saudi patients with relapsing-remitting multiple sclerosis (RRMS). This oral therapy demonstrated well-tolerated outcomes, similar to international studies, supporting its use in RRMS management.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- Fingolimod is an oral disease-modifying therapy for relapsing-remitting multiple sclerosis (RRMS).
- It is the first oral treatment approved for reducing clinical relapses and delaying disability progression in RRMS patients.
- This study evaluates fingolimod's effectiveness in a Saudi Arabian RRMS population.
Purpose of the Study:
- To assess the clinical and radiological outcomes of Saudi patients with active RRMS treated with fingolimod.
- To evaluate the efficacy and safety of fingolimod in a real-world, multicenter setting.
Main Methods:
- A retrospective, multicenter observational study was conducted.
- Included were 100 patients diagnosed with RRMS (revised McDonald criteria) treated with fingolimod for at least 6 months.
- Data collected included disease duration, fingolimod treatment duration, Expanded Disability Status Scale (EDSS) scores, annualized relapse rates, and MRI findings.
Main Results:
- Fingolimod significantly reduced the mean annualized relapse rate from 1.24 to 0.43 (P = 0.001).
- Radiological activity on MRI also showed significant improvement compared to baseline.
- The Expanded Disability Status Scale (EDSS) scores remained stable, indicating disease stabilization.
Conclusions:
- Fingolimod is effective in reducing clinical and radiological disease activity in Saudi RRMS patients.
- Outcomes observed in this study are comparable to international findings.
- Fingolimod appears to be well-tolerated in this multiple sclerosis population.
